Seres Therapeutics, Inc.
$8.94
▲
4.63%
2026-04-21 08:05:00
www.serestherapeutics.com
NMS: MCRB
Explore Seres Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$85.7 M
Current Price
$8.94
52W High / Low
$29.98 / $6.53
Stock P/E
15.05
Book Value
$4.63
Dividend Yield
—
ROCE
-79.05%
ROE
19.64%
Face Value
—
EPS
$0.64
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
66
Beta
0.26
Debt / Equity
187.63
Current Ratio
2.56
Quick Ratio
2.56
Forward P/E
-0.91
Price / Sales
101.09
Enterprise Value
$116.96 M
EV / EBITDA
-1.3
EV / Revenue
148.24
Rating
Strong Buy
Target Price
$22
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Short-term liquidity looks comfortable.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Leverage is relatively high.
- Operating margin is thin.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Protara Therapeutics, Inc. | $5.3 | — | $286.65 M | — | -32.51% | -31.6% | $7.82 / $2.77 | $3.67 |
| 2. | Foghorn Therapeutics Inc. | $5.51 | — | $310.52 M | — | -59.34% | 96.45% | $6.95 / $3.27 | $-1.92 |
| 3. | Atrium Therapeutics, Inc. | $14.3 | — | $239.4 M | — | -32.47% | -104.92% | $73.06 / $11.95 | $-4.04 |
| 4. | CAMP4 THERAPEUTICS CORPORATION | $4.51 | — | $233.12 M | — | -50.89% | -1.45% | $7.75 / $1.3 | $0.92 |
| 5. | Catalyst Pharmaceuticals, Inc. | $26.07 | 14.85 | $3.18 B | — | 26.94% | 25.49% | $26.58 / $19.05 | $7.79 |
| 6. | Arcellx, Inc. | $115 | — | $6.73 B | — | -50.64% | -53.42% | $115.13 / $47.86 | $6.95 |
| 7. | UroGen Pharma Ltd. | $24.92 | — | $1.21 B | — | -81.06% | 268.63% | $30 / $3.42 | $-2.18 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.79 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -19.38 M | -22.48 M | -24.88 M | -27.24 M | -28.84 M | — |
| Net Profit | -15.34 M | 8.2 M | -19.86 M | 32.68 M | -15.64 M | — |
| EPS in Rs | -1.6 | 0.86 | -2.07 | 3.41 | -1.63 | 11.63 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.79 M | 0 M | 0 M | 0 M |
| Operating Profit | -93.97 M | -121.31 M | -195.1 M | -179.91 M |
| Net Profit | 5.7 M | 0.14 M | -113.72 M | -250.16 M |
| EPS in Rs | 0.59 | 0.01 | -11.86 | -26.1 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 138.19 M | 139.81 M | 358.6 M | 348.78 M |
| Total Liabilities | 93.97 M | 126.03 M | 403.46 M | 338 M |
| Equity | 44.22 M | 13.78 M | -44.86 M | 10.78 M |
| Current Assets | 49.38 M | 38.67 M | 175.41 M | 194.76 M |
| Current Liabilities | 19.32 M | 41.22 M | 98.66 M | 85.6 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 1.12 M | -148.61 M | -117.35 M | -228.82 M |
| Investing CF | -0.04 M | 142.29 M | 10.58 M | 82.43 M |
| Financing CF | 13.9 M | -90.37 M | 71.7 M | 129.6 M |
| Free CF | 0.86 M | -148.99 M | -125.33 M | -238.64 M |
| Capex | -0.25 M | -0.38 M | -7.97 M | -9.82 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 100.12% | 54.54% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-04-22 | 1:0.05 |